Original ArticlesLocal Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Key Words
Cited by (0)
Disclosures: Dr. Riely has consulted for AstraZeneca, Boehringer Ingelheim, Chugai, Ariad, Tragara, Daiichi, Novartis, Abbott Molecular, and Celgene, and has received grants from Infinity Pharmaceuticals, Bristol-Myers Squibb, Novartis, Chugai, Pfizer, Merck, and GlaxoSmithKline. Dr. Riely has also had travel expenses covered by Bristol-Myers Squibb. Dr. Solomon has consulted for Johnson and Johnson and Covidien, and has received grants from GE Healthcare and AngioDynamics. Dr. Miller is currently employed by and owns stock in Foundation Medicine. Dr. Miller also has a patent issued from Molecular T790M for detection of EGFR T790M. Dr. Krug has consulted for Genentech. Dr. Kris has received grants from Pfizer and Boehringer Ingelheim, and has consulted for Pfizer, Boehringer Ingelheim, Genentech/Roche, Millenium Pharmaceuticals, Bind Biosciences and Covidien. The other authors declare no conflicts of interest.